The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth.

Background: The mechanistic target of rapamycin complex 1 (mTORC1) is a nutrient-sensing pathway and a key regulator of amino acid and glucose metabolism. Dysregulation of the mTOR pathways is implicated in the pathogenesis of metabolic syndrome, obesity, type 2 diabetes, and pancreatic cancer.

Objectives: We investigated the impact of inhibition of mTORC1/mTORC2 and synergism with metformin on pancreatic tumor growth and metabolomics.

Methods: Cell lines derived from pancreatic tumors of the KPC (Kras; p53; Pdx1-Cre) transgenic mice model were implanted into the pancreas of C57BL/6 albino mice ( = 10/group). Two weeks later, the mice were injected intraperitoneally with daily doses of ) Torin 2 (mTORC1/mTORC2 inhibitor) at a high concentration (TH), ) Torin 2 at a low concentration (TL), ) metformin at a low concentration (ML), ) a combination of Torin 2 and metformin at low concentrations (TLML), or ) DMSO vehicle (control) for 12 d. Tissues and blood samples were collected for targeted xenometabolomics analysis, drug concentration, and cell signaling.

Results: Metabolomic analysis of the control and treated plasma samples showed differential metabolite profiles. Phenylalanine was significantly elevated in the TLML group compared with the control (+426%,  = 0.0004), whereas uracil was significantly lower (-38%,  = 0.009). The combination treatment reduced tumor growth in the orthotopic mouse model. TLML significantly decreased pancreatic tumor volume (498 ± 104 mm; 37%; < 0.0004) compared with control (1326 ± 134 mm; 100%), ML (853 ± 67 mm; 64%), TL (745 ± 167 mm; 54%), and TH (665 ± 182 mm; 50%) (ANOVA and post hoc tests). TLML significantly decreased tumor weights (0.66 ± 0.08 g; 52%) compared with the control (1.28 ± 0.19 g; 100%) (< 0.002).

Conclusions: The combination of mTOR dual inhibition by Torin 2 and metformin is associated with an altered metabolomic profile and a significant reduction in pancreatic tumor burden compared with single-agent therapy, and it is better tolerated.